Introduction {#Sec1}
============

Familial hypercholesterolemia (FH; MIM 143890) is an autosomal dominant genetic disease characterized by high levels of low-density lipoprotein cholesterol (LDL-C), cutaneous xanthomas and premature coronary artery disease (pCAD), which has recently become a major health concern around the world \[[@CR1]\]. Data suggest that 1 in 200 of Caucasians are heterozygous for FH and that 1 in 160,000--300,000 are homozygous \[[@CR2]\], which are much higher prevalences than those estimated a decade earlier \[[@CR3]\]. A study in China has suggested a prevalence of probable or definite FH of 0.28% (1.4/500) based on the modified Dutch Lipid Clinic Network (DLCN) definition \[[@CR4]\]. These studies suggest that nearly 36 million people around the world have potential FH, including 3.8 million in China. FH remains largely underdiagnosed and undertreated. Fewer than 1% of FH cases are diagnosed in most countries, except in some countries of western Europe \[[@CR2]\].

Timely detection of FH is important because the presence of definite or probable FH increases 13-fold (95%CI = 10--17) risk of CAD compared to the general population \[[@CR5]\]. In Europe, FH occurs in up to 8% of patients admitted for acute coronary syndromes, a frequency that is 10 times higher than in the general population \[[@CR6]\]. For patients with acute coronary syndromes, the diagnosis of FH during hospitalization helps to ensure the use of high-dose statins and the management of blood lipids after discharge \[[@CR7]\].

Whether FH in CAD alters the clinical manifestations of the disease and the prognosis of patients is unclear. We compared the long-term prognosis of young patients with and without FH after a coronary event.

Methods {#Sec2}
=======

Study population {#Sec3}
----------------

Patients with both gender (≥18 years and \< 40 years of age) with the following first or recurrent clinical diagnoses or procedures at Beijing Anzhen Hospital from January 2004 to January 2015 were consecutively enrolled in this retrospective study, including those with elective or primary PCI, elective or emergency CABG, acute myocardial infarction (AMI: ICD-10 I21), and acute myocardial ischemia (ICD-10 I20) \[[@CR8]\]. The diagnosis of every participate enrolled in this study was confirmed by two experienced cardiologists.

Patients were excluded if blood lipid data were missing or if the patients had infectious or systematic inflammatory disease, significant hematologic disorders, thyroid dysfunction, severe liver and/or renal dysfunction, or malignant tumors. The study was approved by the Institutional Ethics Committee of Beijing Anzhen Hospital. The Ethics Committee waived the requirement for informed consent because of the retrospective nature of the study.

Patients enrolled in the study were diagnosed with FH based on the DLCN criteria (Table [1](#Tab1){ref-type="table"}), which are endorsed by ESC/EAS guidelines \[[@CR9]\]. Patients were classified as having possible FH if their DLCN score was 3--5, "definite" FH was \> 8, "probable" FH was 6\~8 \[[@CR10]\]. In our study, we combined the categories "definite" FH and "probable" FH into one category (definite/probable FH). Family history of elevated LDL-C was not available for our study sample, so this information was counted as '0' in the DLCN algorithm. Similarly, genetic tests of FH were not conducted and were counted as '0'.Table 1Dutch Lipid Clinic Network criteria for diagnosis of heterozygous familial hypercholesterolaemia in adultsCriteriaPointsFamily HistoryA First degree relative with known premature (\< 55 years men; \<  60 years women) coronary disease and vascular disease OR LDL-c \> 95th percentile1B First degree relative with tendon xanthomata and/or arcuscornealis OR childhood (\< 18 years) with LDL-c \> 95th percentile2Clinical historyA Patient with premature CAD (men \<55, women \<60 years)2B Patient with premature cerebral or PVD (men \<55, women \<60 years)1Physical ExaminationA Tendon xanthomas6B Premature arcus4biochemical results (LDL cholesterol)A LDL -- c \>  8.5 mmol/L8B LDL-c 6.5--8.4 mmol/L5C LDL- c 5.0--6.4 mmol/L3D LDL -- c 4.0--4.9 mmol/L1molecular genetic testing (DNA analysis)DNA mutations8Definite FH: \>  8 points, Probable FH: 6--8 points, Possible FH: 3--5

Patient assessment {#Sec4}
------------------

Data on clinical characteristics were collected based on review of medical records or patient interviews. All patients underwent clinical examination, blood testing and angiography. Peripheral blood samples were drawn from patients within 24 h after admission, and lipid profiles and other assays were performed using an automated biochemical analyzer. LDL-cholesterol concentrations were multiplied by 1.43 in individuals using cholesterol lowering medication before admission \[[@CR11]\]. Hypertension was defined according to the 2010 Hypertension Prevention and Treatment Guidelines \[[@CR12]\] as systolic blood pressure ≥ 140 mmHg and/or diastolic blood pressure ≥ 90 mmHg or the taking of antihypertensive medication. Diabetes mellitus was defined according to the American Diabetes Association (ADA) Diabetes Diagnostic Criteria \[[@CR13]\]. Data were collected on smoking status and body mass index (BMI). After release from hospital, patients were followed up through phone interviews, review of hospital records or outpatient visits.

The primary outcome was main adverse cardiovascular and cerebrovascular events (MACCE), which were defined as cardiac death, acute myocardial infarction, acute decompensated heart failure requiring hospitalization, cerebrovascular events or ischemia-driven revascularization. Ischemia-driven revascularization was defined as repeated PCI or CABG of lesions in the presence of acute myocardial infarction, unstable or stable angina, or documented silent ischemia.

Statistical analysis {#Sec5}
--------------------

Continuous variables were presented as the mean ± standard deviation (SD) if the data were normally distributed. Otherwise, the data were presented as median and interquartile range (IQR). Categorical variables were expressed as frequencies and percentages. Differences in clinical characteristics between patients with or without FH were assessed for significance using one-way ANOVA, χ^2^ tests or the Kruskal-Wallis rank test. Hazard ratios (HRs) and corresponding 95% confidence intervals (CIs) were calculated using Cox proportional hazard models. Event-free survival was analyzed using the Kaplan-Meier method, and inter-group differences in survival were assessed for significance using the log-rank test. All statistical calculations were performed in SPSS 22 (IBM, Chicago, IL, USA), with *p* \< 0.05 defined as indicating significance.

Results {#Sec6}
=======

Baseline characteristics {#Sec7}
------------------------

Among 865 participants, 37 (4.3%) had definite/probable FH and 259 (29.9%) had possible FH, respectively. The remaining 569 (65.8%) received DLCN scores of "unlikely FH" and so were classified as not having FH (Table [2](#Tab2){ref-type="table"}). Unstable angina pectoris is the main cause of hospitalization in FH patients (56.8%), while ST-segment elevation myocardial infarction (STEMI) is a common cause of hospitalization in non-FH patients (57.3%). Compared with patients without FH, those with definite or probable FH were younger but showed higher prevalence of multi-vessel disease (75.7% vs 34.1%), chronic total occlusion (CTO) (45.9% vs 29.9%)and greater coronary severity based on Gensini score (50 vs 32). More patients with definite or probable FH received bypass grafting than those without FH (32.4% vs 10.7%) (Table [3](#Tab3){ref-type="table"}). When discharge, 75.7% of patients with definite or probable FH were on statin therapy, 24.3% on a combination of statin and ezetimibe, and 5.4% on high-dose statin.Table 2Baseline characteristics of young patients after a coronary event with or without FHVariableTotalFH status^a^Probable/Definite\
(\> 5 points)Possible\
(3--5 points)None\
(\< 3 points)*P*Number, n (%)865 (100)37 (4.3)259 (29.9)569 (65.8)Demographics Age, yr33 (30--34)31 (28--31)33 (31--35)33 (30--34)0.005 Female, n(%)49 (5.7)2 (5.4)15 (5.8)32 (5.6)0.993 BMI, kg/m^2^27.8 (4.09)26.5 (4.58)28.3 (3.82)27.7 (4.15)0.057 Family history of pCAD, n(%)199 (23.0)21 (56.8)178 (68.7)0 (0.0)0.000 Smoking status, n(%)586 (67.7)28 (75.7)177 (68.3)381 (67.0)0.531 Elevated alcohol consumption, n(%)208 (24.0)9 (24.3)55 (21.1)144 (25.3)0.445Past history Hypertension, n(%)318 (36.8)7 (18.9)110 (42.5)201 (35.3)0.013 Diabetes mellitus, n(%)138 (16.0)2 (5.4)46 (18.0)90 (15.7)0.145 Pre-existing CAD, n(%)162 (18.7)8 (21.6)45 (17.6)109 (19.1)0.792Lipid profiles TC, mmol/L4.58 (1.46)8.10 (2.35)5.02 (1.33)4.15 (1.00)0.000 LDL-C, mmol/L2.92 (1.24)6.37 (2.13)3.30 (1.12)2.53 (0.71)0.000 HDL-C, mmol/L0.90 (0.20)0.91 (0.19)0.91 (0.21)0.89 (0.20)0.472 TG, mmol/L1.90 (1.29--2.78)1.56 (1.11--2.55)2.01 (1.50--2.98)1.83 (1.27--1.74)0.017*FH* familial hypercholesterolemia, *pCAD* premature coronary artery disease, *BMI* body mass index, *TC* total cholesterol, *LDL-C* low-density lipoprotein cholesterol, *HDL-C* low-density lipoprotein cholesterol, *TG* triglyceride^a^Based on Dutch Lipid Clinic Network criteriaTable 3Clinical features, angiographic characteristics, and treatment of young patients after a coronary event with or without FHVariableTotalFH status^a^Probable/Definite\
(\> 5 points)Possible\
(3--5 points)None\
(\< 3 points)*P*Diagnosis STEMI, n(%)468 (54.1)16 (43.2)126 (48.6)326 (57.3)0.027 NONSTEMI, n(%)75 (8.7)0 (0.0)29 (11.2)46 (8.1)0.054 UAP, n(%)314 (36.3)21 (56.8)101 (39.0)192 (33.7)0.010 SAP, n(%)8 (0.9)0 (0.0)3 (1.2)5 (0.9)0.774Coronary angiography None, n(%)100 (11.6)1 (2.7)33 (12.7)66 (11.6)0.216 Single vessel, n(%)448 (51.8)8 (21.6)131 (50.6)309 (54.3)0.001 Double vessel, n(%)195 (22.5)13 (35.1)57 (22.3)125 (21.9)0.173 Triple vessel, n(%)110 (12.7)13 (35.1)34 (13.1)63 (11.1)0.000 Left main, n(%)61 (7.1)3 (8.1)13 (5.0)45 (7.9)0.312 CTO, n(%)270 (31.2)17 (45.9)83 (32.2)170 (29.9)0.115 Multivessel lesion, n (%)317 (36.6)28 (75.7)95 (36.7)194 (34.1)0.000 Gensini32 (10--64)50 (14--82)32 (10--64)32 (9--56)0.008Operation PCI, n(%)539 (62.3)20 (54.1)176 (68.0)343 (60.3)0.061 CABG, n(%)90 (10.4)12 (32.4)17 (6.6)61 (10.7)0.000 PTCA, n(%)20 (2.3)0 (0.0)6 (2.3)14 (2.5)0.628Medication at discharge Aspirin, n(%)819 (94.7)36 (97.3)251 (96.9)532 (93.5)0.098 β-blocker, n(%)701 (81.0)26 (70.3)216 (83.4)459 (80.7)0.151 ACEI/ARB, n(%)472 (54.6)13 (35.1)146 (56.4)313 (55.0)0.049 Statins, n(%)719 (83.1)28 (75.7)226 (87.3)465 (81.7)0.067 High-dose statins, n(%)67 (7.7)2 (5.4)21 (8.1)44 (7.7)0.847 Ezetimibe, n(%)40 (4.6)9 (24.3)15 (5.8)16 (2.8)0.000*FH* familial hypercholesterolemia, *pCAD* premature coronary artery disease, *STEMI* ST-segment elevation myocardial infarction, *NONSTEMI* Non-ST-segment elevation myocardial infarction, *UAP* Unstable angina pectoris, *SAP* Stable angina pectoris, *CTO* chronic total occlusion, *CABG* coronary artery bypass grafting, *PCI* percutaneous coronary intervention, *PTCA* percutaneous transluminal coronary angioplast, *ACEI/ARB* angiotensin converting enzyme inhibitors/angiotensin receptor blocker^a^Based on Dutch Lipid Clinic Network criteria

The association between FH and risk of MACCE {#Sec8}
--------------------------------------------

Follow-up data were available for 708 (81.8%) patients, while the remaining patients were lost to follow-up, such as because they moved or changed their telephone number. During follow-up, which lasted for a median of 5 (3--8) years, one patient without FH died of leukemia and one without FH died of a brain tumor. These two patients were excluded from the follow-up analysis. Among the remaining 706 follow-up patients, 127 (18.0% of all patients followed-up) experienced a cardiovascular event, which was myocardial infarction in 36 cases (5.1% of all patients followed-up) and cardiac deaths in 15 cases (2.1% of all patients followed-up), respectively. In an unadjusted model, patients with definite or probable FH were at 2.34-fold higher risk of MACCE than those without FH (HR = 2.34, 95%CI = 1.17--4.68, *p* = 0.016). In a multivariable model adjusted for age and sex, patients with definite or probable FH were at 2.39-fold higher risk of MACCE than patients without FH (HR = 2.39, 95%CI = 1.19--4.78, *p* = 0.014). These HR estimates did not decrease when the multivariable model also adjusted for BMI, smoking, hypertension, and diabetes mellitus (HR = 2.30, 95%CI = 1.09--4.84, *p* = 0.028) (Table [4](#Tab4){ref-type="table"}).Table 4Multivariable analysis of the association between FH and risk of MACCEFH status^a^Participants\
(n)MACCE\
(n)Incidence rate\
(per 100 person-y)Unadjusted\
HR (95% CI)Model 1\
HR (95% CI)Model 2\
HR (95% CI)No FH (Score \< 3)453732.51.00 (Referent)1.00 (Referent)1.00 (Referent)Possible FH (Score 3--5)223453.31.30 (0.89--1.88)1.30 (0.90--1.89)1.16 (0.77--1.75)Probable/Definite FH(Score \> 5)3095.82.34 (1.17--4.68)2.39 (1.19--4.78)2.30 (1.09--4.84)*FH* familial hypercholesterolemia, *MACCE* major adverse cardiovascular and cerebrovascular events, *HR* hazard ratio, *CI* confidence interval. Model 1, adjusted for age and sex. Model 2, adjusted for age, sex and cardiovascular risk factors, including current smoking, hypertension, diabetes mellitus, and BMI^a^Based on Dutch Lipid Clinic Network criteria

Discussion {#Sec9}
==========

This study suggests that the prevalence of definite or probable FH among young patients after a coronary event was 4.3%, while that of possible FH was 29.9%, based on the DLCN algorithm. In our cohort, FH was associated with more serious coronary lesions and greater prevalence of multi-vessel disease, despite being associated with younger age. FH was independently associated with increased risk of MACCE during long-term follow-up. Our study suggests that timely diagnosis of FH may help stratify the risk of future MACCE in young patients after a coronary event, as well as identify patients whose close relatives should be screened.

Due to lack of national data, we cannot compare our measured prevalence of 4.3% for definite or probable FH in our cohort with statistics for the population of CAD patients or the general population in China. A single-center study in China reported a prevalence of 3.9% for definite or probable FH in patients with acute myocardial infarction and 7.1% in patients with premature myocardial infarction \[[@CR14]\]. A European multi-country study involving 1451 patients with premature acute coronary syndrome and younger than 55 years (men) or 60 years (women) reported prevalence of 4.8% for definite or probable FH and 47.1% for possible FH \[[@CR6]\].

As a hereditary disease, the clinical diagnostic criteria of FH can identify FH rapidly and costly. We found that patients with definite or probable FH, despite their younger age, exhibited more severe coronary atherosclerosis and higher prevalence (75.7%) of multi-vessel lesions than patients without FH (34.1%). Patients with FH tend to receive lipid-lowering treatment relatively late, when severe atherosclerosis has developed, and the efficacy of lipid-lowering therapy may be reduced. In addition, we found that few of patients with FH in this study were discharged on high-dose statin therapy. Instead, our clinicians preferred to use moderate doses of statins on their own or combined with ezetimibe or bile acid sequestrants in order to enhance lipid-lowering therapy while minimizing the statin-associated risk of elevated liver enzymes and creatine kinase. Statin monotherapy fails to achieve optimal LDL-C levels in most patients with FH \[[@CR15]\]. More effective lipid-lowering strategies include high-dose statin in combination with evolocumab \[[@CR16], [@CR17]\] or ezetimibe. Bile acid sequestrants are rarely used because of their adverse gastrointestinal side effects and poor patient compliance. Colesevelam has stronger ability to bind bile acid. Monotherapy with colesevelam reduced LDL cholesterol by 13--19% and additional 18% in combination with statins \[[@CR18]\]. While treatment for CAD patients with FH remains to be optimized, statins can substantially improve prognosis: modest doses of statins can reduce risk of CAD by about 80% in patients with FH \[[@CR19]\], and a prospective registry study involving 3382 patients with FH showed that statins can reduce coronary mortality by 30% \[[@CR20]\].

With regard to clinical outcomes, we found that definite or probable FH had a \> 2-fold increase MACCE during a long-term follow-up comparing with the patients without FH. This association between FH clinical diagnosis and MACCE was independent of conventional risk factors. Since the lipid-lowering therapy in patients with FH is generally quite late, the coronary artery lesions in patients with FH are more serious. This may be one of the reasons for the adverse outcomes in these patients. In addition, even after a coronary event, the rate of high-dose statin therapy in FH patients was fairly inadequate in this cohort. These patients were still exposed to high levels of LDL-C. Furthermore, though some patients with FH were treated with high-dose statin combined with ezetimibe, part of them still could not attain the desirable targets of LDL-C levels. For these patients, novel lipid-lowering drugs such as proprotein convertase subtilisin kexin 9 inhibitors are expected to further decrease the LDL-C levels and improve cardiovascular outcomes \[[@CR21], [@CR22]\].

In conclusion, early diagnosis and treatment are crucial for improving the outcomes of FH patients. Screening for FH may allow timelier and therefore more effective lipid management in CAD patients with FH. It may also identify patients whose close family members should be screened for FH in order to ensure timely intervention to prevent cardiovascular events.

Limitations {#Sec10}
-----------

The results of this study should be interpreted with caution in light of several limitations. One is the retrospective design, although all patients were followed up prospectively. Secondly, we did not perform genetic molecular analysis to identify heterozygous FH patients. In addition, not all patients received similar treatment. Finally, family history of elevated LDL-C was not available for the presents study, which might underestimate the prevalence of FH in this population.

Conclusions {#Sec11}
===========

It is necessary to optimize lipid treatment of patients with FH after a coronary event. This study provides evidence that FH is an independent risk factor for long-term MACCE in young patients after a coronary event.
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